why choose us

First received: September 03, 2022

Clinical Trial: Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Graft vs Host Disease

Study Type: INTERVENTIONAL


Official Title: Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Brief Summary: Background:Chronic graft-versus-host disease (cGVHD) is an immune system disorder that can occur in people who have had a stem cell transplant.cGVHD can affect multiple organs and increase risk of disability and death.New treatments are needed to treat cGVHD after stem cell transplant.Objective:To test a drug (pacritinib) in people with moderate or severe cGVHD that has not responded to previous treatment.Eligibility:People aged 18 years and older with moderate or severe cGVHD that has not responded to 2 or more…

Read more